TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05300035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of placebo (saline solution) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria.
Study: NCT06013371
Drug: Placebo Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT05015192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, orally
Study: NCT04630756
Drug: AZD4573
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4573 will be administered as an absolute (flat) dose, 2-hour (± 15 minutes) IV infusion once weekly (as monotherapy for Module 2 only) and in combination with orally administered acalabrutinib twice daily continuously. For both Part A and Part B of this study, Cycle 1 consists of 5 weeks, with a dose ramp-up. Subsequent cycles are 21 days (3 weeks) with once weekly dosing of AZD4573 in combination with acalabrutinib twice daily continuously (in Module 1 and Module 2, period 2).
Study: NCT05770310
Drug: JS015
Normalized name: Janus Kinase Inhibitor JS015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient receives specific dose of JS015. The administration method of JS015 is intravenous infusion.
Study: NCT05025865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo will be given in capsule form to study participants.
Study: NCT06647628
Drug: MK-1708
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1708 oral suspension
Study: NCT06647628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral suspension
Study: NCT06647862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06199089
Drug: CM313 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CM313 administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to experimental group were treated with CD38 monoclonal antibody (CM313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment.
Study: NCT05061550
Drug: AZD0171
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD0171 via intravenous route.
Study: NCT05987371
Drug: TQC3721 suspension for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC3721 suspension for inhalation is a dual inhibitor targeting PDE3/4.
Study: NCT05987371
Drug: Salbutamol sulfate inhalation aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol is short-acting β2 receptor agonists.
Study: NCT05960526
Drug: extract Binahong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract Binahong 2.5% as nasal irrigation solution
Study: NCT05960526
Drug: Isotonic saline nasal irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% as nasal irrigation solution
Study: NCT05309421
Drug: EVX-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug given in combination with standard of care
Study: NCT05198050
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tables with a similar appearance to letrozole
Study: NCT04650490
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice of immunotherapy per standard of care
Study: NCT06049953
Drug: Antipsychotics
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medications are widely prescribed for severe mental illness such as affective and non-affective psychosis, mood stabilization, and augmentation of unipolar depression.
Study: NCT05030818
Drug: Polypill of acetylsalicylic acid, ramipril and atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of acetylsalicylic acid, ramipril and atorvastatin in a polypill during 3 months more
Study: NCT06049953
Drug: Non-antipsychotic medication
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medications are typically prescribed to manage symptoms of anxiety, depression, psychological distress, and/or insomnia.
Study: NCT05030818
Drug: Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be receiving during 3 months more the same components acetylsalicylic acid, ramipril and atorvastatin than with the polypill
Study: NCT06222749
Drug: Intranasal placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray solution; Placebo will be administered as the placebo controlled condition.
Study: NCT06311786
Drug: [14C]-BIIB091
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT04699630
Drug: U3-1402
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 of every 3 weeks. One cycle is defined as 3 weeks.
Study: NCT06015659
Drug: Zentalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol.
Study: NCT06437496
Drug: 68Ga-PSMA-11//68Ga-PSMA-617
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-PSMA-11//68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-11/68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
Study: NCT06280378
Drug: KL003 Cell Injection Drug Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion after myeloablative conditioning with busulfan.
Study: NCT05046353
Drug: D-serine
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory remediation +/-D-serine
Study: NCT06444867
Drug: LEO 158968
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC injection
Study: NCT05169554
Drug: Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be rifampicin (600 mg, daily) and clarithromycin (500 mg, twice daily) for 8 weeks. On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.
Study: NCT06192277
Drug: Standard dose Penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who have taken the low dose of oral penicillin and have had no reaction are provided a second higher dose of penicillin (250mg) and observed for 60 minutes.
Study: NCT06435676
Drug: HRS9531
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose escalation of HRS9531 tablets in healthy subjects
Study: NCT06435676
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo in healthy adults
Study: NCT06435676
Drug: HRS9531
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose escalation of HRS9531 tablets in healthy subjects
Study: NCT06435676
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of placebo in healthy adults
Study: NCT04784715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion
Study: NCT04784715
Drug: Taxane
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion
Study: NCT04857502
Drug: 99mTc-based PSMA Imaging and Surgery Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given via IV injection
Study: NCT05948579
Drug: Intervention B Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.
Study: NCT00257374
Drug: Gatorade, Pedialyte and New Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05197556
Drug: HSG4112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral administration
Study: NCT05197556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral administration
Study: NCT05265806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An identical amount of intranasal administration of placebo (identical ingredients except the peptide - i.e. glycerine and sodium chloride) will be assigned to each subject.
Study: NCT05915702
Drug: Gadoquatrane (BAY1747846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study: NCT04850937
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group will be given 0.5ml/kg normal saline intravenously after anesthesia induction
Study: NCT06414954
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets taken twice a day for 21 days
Study: NCT04989946
Drug: FLT PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms 1-3 only, FLT PET/CT scan at baseline (within 1-6 days of Day 1) and Day 43
Study: NCT06460506
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination granules for oral administration.
Study: NCT06578624
Drug: SA53-OS (phase 1)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose escalation phase in which participants receive SA53-OS on 3 consecutive days every 3 weeks for a maximum of 2 years. Single participant cohorts will be enrolled until a Grade 2 or greater toxicity is observed and then 3+3 multi-participant cohorts will be enrolled until the MTD is identified.
Study: NCT06578624
Drug: SA53-OS (phase 2)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose expansion phase in which participants receive SA53-OS on 3 consecutive days every 3 weeks for a maximum of 2 years at the MTD identified in phase 1.
Study: NCT06304883
Drug: Experimental: ALZ-801
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALZ-801 265 mg BID tablet orally.
Study: NCT06577116
Drug: AK006 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation for intravenous infusion
Study: NCT06576037
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by vein (IV)
Study: NCT06572397
Drug: H-1337 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution
Study: NCT05426395
Drug: Vitamin B12 2.6 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: There are four groups of women (n = 20 total) who will receive B12 dosing once daily, including group 1a (sufficient baseline B12, pregnant), group 1b (sufficient baseline B12, non-pregnant), group 1c (insufficient baseline B12, pregnant), and group 1d (insufficient baseline B12, non-pregnant).
Study: NCT05426395
Drug: Vitamin B12 50 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants (n = 20 total) will be randomly assigned to receive either a once per day B12 dose or a twice per day B12 dose. The four groups at this dose level include: group 3a (sufficient baseline B12, pregnant, Q12), group 3b (sufficient baseline B12, Q24), group 3c (insufficient baseline B12, pregnant, Q12), group 3d (insufficient baseline B12, Q24).
Study: NCT06462235
Drug: Part A: ATM-AVI Single Dose, Cohorts 1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of aztreonam-avibactam over 3 hours to assess pharmacokinetics, safety, and toleration.
Study: NCT06462235
Drug: Part B: Multiple-dose ATM-AVI, Cohorts 1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intravenous infusions of aztreonam-avibactam over 3 hours, repeated every 6-8 hours up to 14 days to assess pharmacokinetics, safety, toleration, and efficacy.
Study: NCT05829148
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin
Study: NCT05409326
Drug: TQH2722 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
Study: NCT05409326
Drug: Placebo to match TQH2722
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
Study: NCT06575075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Saline
Study: NCT06119685
Drug: IDP-023
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK cell therapy
Study: NCT06119685
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting chemotherapy
Study: NCT04872257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally daily for 6 months
Study: NCT04920149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IMP will be supplied as sachets with slow-releasing granules.
Study: NCT05121233
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a single dose 75 mg IV diclofenac by infusion prior to the procedure
Study: NCT05121233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose iv placebo (saline ) by infusion prior to the procedure
Study: NCT04768179
Drug: 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin for 14 days plus ivermectin at 200 mcg/kg/day or 600 mcg/kg/day for 3 days
Study: NCT05435638
Drug: KM-001 1% cream 12 weeks treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves.
Study: NCT05435638
Drug: KM-001 1% cream 16 weeks treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves.
Study: NCT04771897
Drug: BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance
Approvals — FDA: no, EMA: no, PMDA: no
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 1, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.
Study: NCT06031012
Drug: CGECC alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received CGECC alone from the beginning of radiotherapy to one week after radiotherapy.
Study: NCT06219473
Drug: subepithelial connective tissue graft
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: The connective tissue is generally taken from the hard palate, although it may be taken from other sites as well, such as the maxillary tuberosity area.
Study: NCT05072314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 0.9% Saline solution.\*~2. Followed by a 0.9% Saline solution intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 0.9% Saline solution infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only
Study: NCT06211049
Drug: Vitex agnus-castus BNO 1095 (20 mg)
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
Study: NCT06211049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
Study: NCT05544734
Drug: Hydrocodone 5Mg/Acetaminophen 325Mg Tab
Normalized name: HYDROCODONE 5MG/ACETAMINOPHEN 325MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/325 mg tablet
Study: NCT05544734
Drug: Acetaminophen 1000mg
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg tablet
Study: NCT05544734
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg tablet
Study: NCT05436652
Drug: SPI-62
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
Study: NCT05436652
Drug: SPI-62 matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive tablets identical in appearance to SPI-62 tablets
Study: NCT05436652
Drug: Prednisolone 10mg
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care prednisolone
Study: NCT05436652
Drug: Additional prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Over encapsulated prednisolone
Study: NCT05436652
Drug: Additional prednisolone matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive capsules identical in appearance to over encapsulated prednisolone
Study: NCT04815083
Drug: Aminolevulinic Acid Hydrochloride
Normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PD G 506 A for oral solution (aminolevulinic acid \[ALA\] hydrochloride \[HCl\] granules for oral solution) is administered as a single dose (20 mg/kg body weight) approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
Study: NCT04815083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo is administered as a single dose approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
Study: NCT06573281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intramuscularly on Day 1 and Day 30 and for RSV_Group F placebo administered only on Day 30.
Study: NCT05960773
Drug: Decitabine/cedazuridine
Normalized name: decitabine/cedazuridine 35 mg-100 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine/cedazuridine (INQOVI) oral tablet (35 mg decitabine and 100 mg cedazuridine) taken 3 consecutive days during the first week of every cycle (1 cycle=28-days) for 6 cycles (i.e., 1 course). Additional 6 cycles (i.e., Course 2) for subjects with stable disease or disease regression. Max (total) of 2 treatment courses.
Study: NCT05007873
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06572631
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06574048
Drug: saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline bolus
Study: NCT06134375
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 twice daily, Days 1-14 Q21days for 6 months
Study: NCT06079359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo via SC injection.
Study: NCT06575959
Drug: Enlicitide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05528588
Drug: Diuretic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive home dose oral furosemide or oral furosemide per standard of care.
Study: NCT06125951
Drug: Xanamem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
Study: NCT06125951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient.
Study: NCT04599634
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication with 650mg acetaminophen 30-60 minutes prior to obinutuzumab doses.
Study: NCT04792567
Drug: BAF312
Approvals — FDA: no, EMA: no, PMDA: no
Description: taken orally once per day (dose depends on CYP2C9 genotype)
Study: NCT04792567
Drug: Baseline disease modifying therapies (DMTs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMTs: Dimethylfumarate, glatirameracetate, interferon, teriflunomode according to respective SmPC
Study: NCT05629585
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active Comparator. Tablet. Oral route of administration
Study: NCT05650879
Drug: ELVN-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT06392295
Drug: Androgen Deprivation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy will be administered as per standard of care.
Study: NCT06392295
Drug: Androgen Receptor Signaling Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor signaling inhibitor (ARSI) will be administered as per standard of care.